Bionorica SE: New Executive Board Member for the Global Business

Dr Marco Linari to join the natural medicine manufacturer in April 2022            

Neumarkt in the Upper Palatinate, 21/01/2022 – Bionorica appoints Dr Marco Linari to the Executive Board leading the Global Business. Dr Linari, who holds a doctorate in biochemistry, will thus be responsible for all marketing and sales activities at Bionorica worldwide as of April 1, 2022.

“With more than 20 years of expertise in the pharmaceutical sector, his leadership track record and international experience, Dr Marco Linari will be instrumental for the growth and further internationalisation of Bionorica. We look forward to having him on board,” says Professor Dr Michael A. Popp, owner and CEO of Bionorica. 

Dr Linari adds: “I am looking forward to joining Bionorica SE with its excellently positioned brands that provide measurable benefits to patients all over the world. With our strong team, the Bionorica family, our high level of expertise in phytotherapy and the product portfolio, we will continue to expand and open up new markets.”

Cross-national and cross-industry experience

Since May 2020, Dr Linari has been CEO of the Stuttgart-based Haselmeier Group, a leading developer and manufacturer of injection systems for subcutaneous medication. While there, he successfully diversified and transformed the business. He studied chemistry and economics and earned his doctorate in biochemistry at the Max Planck Institute for Molecular Physiology in Dortmund. After a successful career in strategy consulting, Dr Marco Linari held leadership roles within the Merck Group in Germany, Switzerland, Italy and the United States, and lastly as CEO of Allergopharma where he fundamentally modernised the business. 

The 51-year-old, a native of Lemgo in North Rhine-Westphalia, has Italian roots, is married and has two teenage children. His passions are skiing and mountaineering as well as Italian cuisine.

Company profile

Patients want effective and tolerable medications and so herbal remedies are the preferred option. Bionorica, based in Neumarkt in Bavaria's Upper Palatinate region, is a leading global manufacturer of scientifically researched phyto-pharmaceuticals. Doctors, pharmacists and patients in more than 40 countries trust the effective herbal medicinal products with few side effects. In 2020 the Bionorica Group achieved a turnover of EUR 289 million. The equity ratio of the company is 80.5 percent. 1,800 employees at 20 Bionorica locations worldwide work every day to continue this success story that began 89 years ago in Nuremberg. Based on its “Phytoneering” strategy, Bionorica unlocks the great potential of active ingredients in plants (phytos) by using state-of-the-art research and technologies (engineering). The result: evidence-based herbal medicinal products. Research and indications are focused on the respiratory tract, the urinary tract, women’s health and the immune system.

Press Contact

Bionorica SE
Lion Pfeufer
Head of Media and Public Relations 
Kerschensteinerstrasse 11-15
92318 Neumarkt, Germany

Phone +49 (0)9181/231-7423
Telefax +49 (0)9181/231-67423
E-mail: unternehmenskommunikation@bionorica.de

http://bionorica.de/fuer-journalisten.html